Take a look at this month’s industry headlines including US FDA approvals for XOFLUZATM and…
Browsing: Drug Development
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘Anti-Candida activity of existing antibiotics and their derivatives when used alone or in combination with antifungals’ as we ask the authors about Candida infections, the potential repurposing of antibiotics and the future of this field.
Take a look at this month’s industry headlines including FDA warnings over hepatitis C drugs in patients with liver injury, a new infectious diseases strategy for the UK and priority review for Merck’s Ebola vaccine.
In this interview, Paul Rowley (University of Idaho, ID, USA) speaks about his research identifying novel antifungal proteins from Saccharomyces cerevisiae yeasts and whether these could be translated into the medications of the future.
In this perspective piece for Future Microbiology the authors argue that there is a lack of innovation to meet the current shortcomings of antibiotic R&D.
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘An update on drug repurposing: Is it useful for tacking antimicrobial resistance?’ as we ask the authors about what challenges and limitations drug repurposing faces, in addition to why this strategy could be a promising alternative to the traditional drug discovery pipeline.
Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
The US FDA has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of specific types of drug-resistant pulmonary tuberculosis.
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
Coagulation factors, which normally function to clot blood, have been demonstrated to have antibacterial action against Gram-negative bacteria in vitro and in mouse models.